Eli Lilly and Co.’s stock jumped Thursday after midstage research on an experimental diabetes drug showed significant weight loss in patients. The news took a toll on shares of rival Novo Nordisk.
The company, which employs more than 3,000 on the northeast side, has been struggling on the diabetes side of its business. To bounce back, it is investing heavily in diagnostics, and is working to commercialize several products it hopes will be game-changers.
The tally of fatalities was nearly twice as large as what health officials previously considered a bad year, the director of Centers for Disease Control and Prevention said.
Of course, Indiana’s improved ranking doesn’t necessarily mean Hoosiers are slimming down, and could simply reflect that other states are getting worse.
A food worker at the restaurant tested positive for the virus and might have infected customers on Aug. 6, according to the Marion County Public Health Department.
The center aims to develop new treatments for diabetes, severe wounds, and damage to tissues and organs caused by age, disease or trauma.
The American Medical Association recently called on regulators to monitor competition among the three drugmakers who control the market—Indianapolis-based Eli Lilly and Co., Denmark-based Novo Nordisk and Paris-based Sanofi.
After decades of being starved of innovative treatments for serious conditions like cancer, diabetes and kidney disease, China’s 1.4 billion people are becoming a prime target for Eli Lilly and other pharmaceutical companies.
The university said it has hired 33 research faculty to help under the “Grand Challenges” program in precision health, an initiative it rolled out two years ago.
While the ultimate outcome remains far from certain, the study is a bright spot—if a tenuous one—in the search for a treatment for Alzheimer’s, where more than 100 experimental drugs have failed.
The Indianapolis-based drugmaker has been working for years to develop the much-anticipated drug, which some analysts had said might ring up $2 billion a year in sales.
New therapies that could cure diseases caused by defective genes will get quicker approval from U.S. regulators, part of an effort by the Food and Drug Administration to keep pace with one of biotechnology’s fastest-growing fields.
City-County Council will consider May 21 whether to launch a syringe exchange program here in an effort to cut down the growing number of hepatitis C cases, which officials are linking to the opioid epidemic.
The newly built farm uses a high-fat, high-cholesterol diet to give animals heart disease and diabetes to help medical researchers find treatments.
A five-year, $7 million program is led and supported by a coalition of local health institutions, including Eli Lilly and Co., Fairbanks School of Public Health and Eskenazi Health. It is based on a model that Lilly has used in other countries.
The Indianapolis-based health system will present details Tuesday to the Carmel Plan Commission for the two-story, 88,000-square-foot building.
Roche Holding AG—the Basel, Switzerland-based parent of Indianapolis-based Roche Diagnostics—has enlisted a little green gremlin to help rescue its diabetes business after a decade of declining sales.
The Food and Drug Administration proposal will create new opportunities for drugmakers after repeated failures from companies including Indianapolis-based Eli Lilly and Co.
Lawmakers stripped a provision from the bill that would have boosted the cigarette tax from 99 cents a pack to $2.99.
The program is for patients with Stage 3 or Stage 4 cancer who had not had success with traditional treatments. Under the program, scientists analyze patients’ genome, leading to a personalized treatment plan.